Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program

Robert Harris\textsuperscript{a,b,*}, Amanda Rosecrans\textsuperscript{a,b}, Meredith Zoltick\textsuperscript{a,b}, Catherine Willman\textsuperscript{a,b}, Ronald Saxton\textsuperscript{a}, Margaret Cotterell\textsuperscript{a,b}, Joy Bell\textsuperscript{a,b}, Ingrid Blackwell\textsuperscript{a,b}, Kathleen R. Page\textsuperscript{a}

\textsuperscript{a} Johns Hopkins University School of Medicine, Baltimore, MD, USA
\textsuperscript{b} Baltimore City Health Department, Baltimore, MD, USA

A R T I C L E   I N F O

Keywords:
Opioid use disorder
Low-threshold
Buprenorphine
Mobile
Retention
Telemedicine

A B S T R A C T

Background: Changes in federal policy during the COVID-19 pandemic allowing for the use of telemedicine to treat opioid use disorder (OUD) have facilitated innovative strategies to engage and retain people in treatment. Since 2018, the Baltimore City Health Department has operated a mobile street medicine program called Healthcare on The Spot (The Spot) that provides treatment for OUD and infectious diseases. This study describes the transition of The Spot’s buprenorphine service to telemedicine during the COVID-19 pandemic and one year treatment retention.

Methods: Patients actively engaged in care at the time of transition to telemedicine and patients newly engaged in buprenorphine services through telemedicine were included in this descriptive analysis and assessed at one year for retention.

Results: From March 16, 2020 to March 15, 2021, The Spot provided voice-only buprenorphine treatment services to 150 patients, 70.7\% (\textit{n} = 106) male and 80.0\% (\textit{n} = 120) Black; 131 were patients who transitioned from in person services and 19 were newly engaged via telemedicine. 80.7\% (\textit{n} = 121) of patients remained engaged in treatment at one year, 16.0\% (\textit{n} = 24) were lost to follow-up, and 3.3\% (\textit{n} = 5) were deceased. Patients newly engaged via telemedicine were more likely to be female and white than those retained from in person services.

Conclusion: The Spot’s transition of patients from a street medicine program to telemedicine during the COVID-19 pandemic has implications for future practice. Increased flexibility of service delivery, extended prescription length, and decreased UDT likely contributed to high retention rates and should inform the future structure of low-threshold buprenorphine programs.

1. Introduction

Temporary changes to U.S. federal regulations allowing for the use of telemedicine, including voice-only technology (Drug Enforcement Agency, 2020), during the COVID-19 pandemic has led to clinical practice and service delivery innovation in the treatment of opioid use disorder (OUD) (Samuels et al., 2020; Nordeck et al., 2020). Though seldomly used in addiction medicine prior to the pandemic, telemedicine has been shown to be effective at engaging and retaining patients on medications for opioid use disorder (MOUD), including buprenorphine (Eibl et al., 2017; Weintraub et al., 2018; Nordeck et al., 2020). As fatal overdoses continue to surge nationally (Mattson et al., 2021), and access to MOUD remains limited (Creedon and Cook, 2016; Lagisetty et al., 2019), research is needed to better understand the implications of these policy changes on patient outcomes.

Baltimore City has the ninth highest overdose rate of any jurisdiction in the U.S. and had 814 opioid-related overdose deaths in 2018 (Maryland Department of Health, 2019). In response, the Baltimore City Health Department (BCHD) started a street-based mobile clinic called Healthcare on the Spot (The Spot) in 2018 to provide integrated, low-threshold OUD and infectious disease treatment in communities experiencing high rates of opioid-related overdose (Rosecrans et al., 2019).
In the first fifteen months of The Spot, 420 patients were engaged in buprenorphine treatment, with three-month retention of 27%. More than three-quarters of patients were Black, and retention in this group was higher than for white patients. This demonstrated the feasibility of public health departments to provide integrated street-based buprenorphine treatment and successfully engage populations that traditionally have barriers to buprenorphine treatment (Hollander et al., 2021).

As the COVID-19 pandemic began in March 2020, The Spot’s clinical operations transitioned from in-person visits to telemedicine in order to mitigate risk of COVID-19 transmission. This study describes how The Spot’s buprenorphine service adapted practices into a telemedicine model, the characteristics of individuals served, and retention rate in buprenorphine treatment after one year of telemedicine service.

2. Material and methods

2.1. Transition from in-person to telemedicine

Prior to COVID-19, the Spot in-person services followed a low-threshold model with same-day medication start, home induction, no required therapy sessions, and allowance for ongoing substance use. As COVID-19 cases increased nationally requiring therapy sessions, and allowance for ongoing substance use threshold model with same-day medication start, home induction, no

2.2. Description of telemedicine service delivery

Four providers (a total of 0.8 full-time equivalent) maintained panels of patients in conjunction with a case manager. Providers performed telemedicine visits with patients and reviewed Maryland’s prescription drug monitoring program prior to each buprenorphine prescription. Due to limited patient access to technology, all visits were voice-only. Visit frequency ranged from one to eight weeks, with most patients on a four-week cycle. Laboratory tests previously obtained at the mobile clinic (e.g., UDT and HIV, STI, and HCV screening tests) were not offered during this period. To determine visit frequency and prescription length, providers assessed the patient’s stability including the number of requested early refills, reported frequency of illicit drug use, and consistency of engagement with the care team. Case managers connected with patients weekly, biweekly, or monthly based on patient need. Prescriptions were called in or electronically prescribed to the patient medicine from March 16, 2020 to March 15, 2021.

Characteristics of patients receiving care from The Spot mobile clinic via telemedicine from March 16, 2020 to March 15, 2021 (Table 1). The majority were male (70.7%), Black (80.0%), and between 50 and 59 years old. The Spot provided telemedicine OUD treatment services to 150 patients from March 16, 2020, to March 15, 2021 (Table 1). The majority were male (70.7%), Black (80.0%), and between 50 and 59 years old.

### Table 1

| Characteristic | Total Engagement Method | p-Value |
|----------------|-------------------------|---------|
|                | N = 150                 |         |
|                | Transitioned from in-person | Started via telemedicine |         |
|                | N = 131                  | N = 19  |         |
| Demographics   |                         |         |         |
| Age            |                         |         |         |
| < 30 years     | 17 (11.3%)              | 15 (11.5%) | 2 (10.5%) | 0.473 |
| 30–49 years    | 55 (36.7%)              | 47 (35.9%) | 8 (42.1%) |         |
| 50–59 years    | 62 (41.3%)              | 54 (41.2%) | 9 (47.4%) |         |
| > 60 years     | 16 (10.7%)              | 15 (11.5%) | 0 (0.0%)  |         |
| Gender         |                         |         |         |
| Female         | 44 (29.2%)              | 34 (26.0%) | 10 (52.6%) | 0.017 |
| Male           | 106 (70.7%)             | 97 (74.0%) | 9 (47.4%)  |         |
| Race           |                         |         |         |
| Black/African  | 120 (80.0%)             | 111 (84.7%) | 9 (47.4%)  | < 0.001 |
| American White | 28 (18.7%)              | 18 (13.7%) | 10 (52.6%) |         |
| Other          | 2 (1.3%)                | 2 (1.5%)   | 0 (0.0%)   |         |
| Ethnicity      |                         |         |         |
| Hispanic/Latinx| 1 (0.7%)                | 1 (0.8%)   | 0 (0.0%)   | 0.702   |
| Not Hispanic/Latinx | 149 (99.3%) | 130 (99.2%) | 19 (100.0%) |         |

2.3. Data management, variable definitions, and statistical analysis

Demographic and clinical data were captured in the electronic medical record (INSIGHT) as part of routine clinical care. Patient characteristics were examined using descriptive statistics. Patients were considered active prior to the transition to telemedicine if they had received a prescription for buprenorphine in the five weeks preceding March 16, 2020. Patients receiving in person services who had at least one telemedicine encounter with a buprenorphine prescription after March 16, 2020, were considered to have transitioned to telemedicine. To account for patients who received prescriptions for four weeks of buprenorphine with one refill, active retention in treatment at the end of the study period was defined as having a prescription for buprenorphine within the nine weeks before March 15, 2021. Chart review was performed to confirm all categorizations of retention status. Pearson’s χ² tests compared demographic characteristics between those who transitioned to telemedicine from in person services to those who were lost to follow-up from in person services. Additionally, Pearson’s χ² tests compared demographic and retention characteristics of those who transitioned to telemedicine from in person services to those who were newly engaged via telemedicine. Johns Hopkins institutional review board determined this study to be quality improvement and exempt from human subjects research.

3. Results

The Spot provided telemedicine OUD treatment services to 150 patients from March 16, 2020, to March 15, 2021 (Table 1). The majority were male (70.7%), Black (80.0%), and between 50 and 59 years old.
structures and introduce a power differential in the provider–patient management of OUD, yet its frequency and overall benefit in OUD was the removal of routine UDT. Routine toxicology screening has been charged for persisting evidence of buprenorphine non-adherence, or treatment outcomes are unclear (Jarvis et al., 2017). Prior to the recommended as a component in the identification, treatment, and PrEP, and testing and treatment for HIV, HCV, and sexually transmitted infections.

There are limitations to this study. First, data are collected for routine medical care and may be incomplete. Second, given our limited ability to accept new patients, the potential for new patient engagement via telemedicine cannot be determined in this study. Third, retention in telemedicine services for patients previously engaged via in-person services may not be comparable to other populations and may not be generalizable.

4. Discussion

Working under U.S. federal policy changes that allowed for the use of voice-only technology in the treatment of OUD, The Spot was able to transition almost 75% of patients who were initiated in a low-threshold, street-based mobile clinic to telemedicine services during the COVID-19 pandemic. Of the 150 patients served through telemedicine, 80% were retained in buprenorphine treatment at one year. This is notably higher than The Spot’s retention rates with in person services of 56% at one month and 26% at three months (Rosecrans et al., 2021). Another street-based buprenorphine program has reported similarly high engagement and one month retention rates with telemedicine during the pandemic (Nordeck et al., 2020). To our knowledge, this is the first study to track retention in a telemedicine buprenorphine program for one year, and adds to the growing evidence for continuation of telemedicine as part of addiction medicine service delivery.

The transition to telemedicine services dramatically changed the structure of service delivery for The Spot. Provider visits and prescription lengths were extended to every four weeks as the standard, with the option to decrease interval length as needed for patients who required additional support. The convenience of the lengthened visit intervals and brief telephone calls without waiting in line to be seen on the van have reduced the burden of participation in The Spot’s buprenorphine program. Frequent and time-consuming visits can be challenging for patients to balance with other needs such as employment and may lead to disengagement in treatment (Silverstein et al., 2020). Providing lengthened visit intervals in conjunction with the benefits of telemedicine including eliminating wait times, transportation needs, and need for childcare, has the potential for removing barriers and improving access to buprenorphine treatment.

Another change that may have contributed to high retention rates was the removal of routine UDT. Routine toxicology screening has been recommended as a component in the identification, treatment, and management of OUD, yet its frequency and overall benefit in OUD treatment outcomes are unclear (Jarvis et al., 2017). Prior to the pandemic, patients on The Spot submitted samples for UDT at every visit. Patients were not discharged for illicit substance use and the information from UDT was used to engage in patient-centered strategies to facilitate recovery goals. Approximately 20% of patients were discharged for persisting evidence of buprenorphine non-adherence, or sample adulteration; oftentimes within weeks of their induction visit (Rosecrans et al., 2021). Frequent UDT can reinforce punitive social structures and introduce a power differential in the provider–patient relationship (Incze, 2021). Implementing a less frequent and more focused UDT protocol has the potential to improve therapeutic relationships (Pytell and Rastegar, 2021). More research is needed to better understand if reduced utilization of UDT can have a positive impact patient engagement. Additionally, standardized assessment tools that focus on patient outcomes rather than UDT are needed to gauge engagement and success in treatment including personal goal achievement, quality of life, and engagement in other services (Incze, 2021).

There are drawbacks to this model. Some patients may prefer the routine of coming to the mobile clinic and interacting with their care team and other patients. Second, a telemedicine-only model could not provide an objective measure of medication adherence, and models that include telemedicine should include access to UDT for this purpose. Third, while telemedicine may provide patients more flexible access to providers than traditional clinic hours, there is a risk of burnout for providers who may feel like they are almost constantly “on call.” Lastly, transitioning to a telemedicine model limited access to much needed services for people with substance use disorder, such as wound care, PrEP, and testing and treatment for HIV, HCV, and sexually transmitted infections.

There are limitations to this study. First, data are collected for routine medical care and may be incomplete. Second, given our limited ability to accept new patients, the potential for new patient engagement via telemedicine cannot be determined in this study. Third, retention in telemedicine services for patients previously engaged via in-person services may not be comparable to other populations and may not be generalizable.

5. Conclusion

New strategies that expand access to OUD treatment remain a critical public health need. The Spot’s successful transition of patients in a low-threshold street medicine program to telemedicine during the COVID-19 pandemic has implications for future practice. Increased flexibility of service delivery, extended prescription length, and decreased UDT likely contributed to high retention rates and should inform the future structure of low-threshold buprenorphine programs.

Role of the funding source

Funding for The Spot services is provided by grants from Maryland’s Opioid Operations Command Center, the Maryland Department of Health, the Ryan White HIV/AIDS Program, and the National Institute on Drug Abuse (R01 DA045556, K24 DA035684). The funding sources had no contribution to the study design, analysis or interpretation of data, or writing of the manuscript.

CRediT authorship contribution statement

Robert Harris, Amanda Rosecrans: Developed and implemented the program, Designed the study, Drafted the manuscript. Meredith Zoltick, Catherine Willman, Joy Bell, Ingrid Blackwell: Contributed to development and implementation of the program, as well as manuscript content. Ronald Saxton: Performed data analysis. Kathleen Page: Contributed to program development and implementation, Study design, Manuscript content. All authors have reviewed and approved the final version of the manuscript.

Conflicts of Interest

None.

Acknowledgments

The authors would like to thank all of the staff of The Spot mobile clinic and all of the patients that have entrusted us with their care. We
would like to thank the Baltimore City Health Commissioner and Deputy Commissioner of Population Health and Disease Prevention, and Assistance Commissioner for believing in and supporting the team. The BCHD Sexual Health and Wellness Clinics, Syringe Services Program, and Opioid Intervention Team have provided essential ongoing collaboration and support. Finally, many pharmacy partners have provided excellent service to our patients during COVID-19 including CareMax pharmacy.

References

Creedon, T.B., Cook, B.L., 2016. Access to mental health care increased but not for substance use, while disparities remain. Health Aff. (Proj. Hope) 35, 1017–1021.

Drug Enforcement Agency, 2020, Use of Telephone Evaluations to Initiate Buprenorphine Prescribing.

Eibl, J.R., Gauthier, G., Pellegrini, D., Daiter, J., Varenbut, M., Hogenbirk, J.C., Marsh, D., C., 2017. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 176, 133–138.

Jarvis, M., Williams, J., Harford, M., Lindsay, D., Lincoln, P., Giles, L., Luongo, P., Safarian, T., 2017. Appropriate Use of Drug Testing in Clinical Addiction Medicine. J. Addict. Med. 11, 163–173.

Hollander, M.A.G., Chang, C.H., Dowinby, A.B., Hulse, E., Donohue, J.M., 2021. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use. Drug Alcohol Depend. 227, 108927.

Ince, M.A., 2021. Reassessing the role of routine urine drug screening in opioid use disorder treatment. JAMA Intern. Med. 181, 1282–1283.

Lagivetty, P.A., Ross, R., Bohnert, A., Clay, M., Maust, D.T., 2019. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry (Chic., Ill.) 76, 979-981.

Maryland Department of Health, 2019, Unintentional Drug- and Alcohol-Related Intoxication Deaths in Maryland, 2018.

Mattson, C.L., Tanz, I.J., Quinn, K., Karis, M., Patel, P., Davis, N.L., 2021. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb. Mortal. Wkly Rep. 70, 202–207.

Nordeck, C.D., Buresh, M., Krawczyk, N., Fingerhood, M., Agus, D., 2020. Adapting a low-threshold buprenorphine program for vulnerable populations during the COVID-19 pandemic. J. Addict. Med.

Pytell, J.D., Rastegar, D.A., 2021. Down the drain: Reconsidering routine urine drug testing during the COVID19 pandemic. J. Subst. Abus. Treat. 120.

Roeckers, A., Harris, R., Saxton, R.E., Cotterell, M., Zolick, M., Willman, C., Blackwell, J., Bell, J., Hayes, D., Weir, R., Sherman, S., Lucas, G.M., Greenbaum, A., Page, K.R., 2021. Mobile low-threshold buprenorphine integrated with infectious disease services. J. Subst. Abus. Treat. 108553.

Samuels, E., Clark, S., Wunsch, C., Jordison Keele, L., Reddy, N., Vanjani, R., Wightman, R., 2020. Innovation during COVID-19: improving addiction treatment access. J. Addict. Med. 14, e8-e9.

Silverstein, S.M., Danilaitisyte, R., Miller, S.C., Martins, S.S., Carlson, R.G., 2020. On my own terms: motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug Alcohol Depend. 210, 107958.

Weintraub, E., Greenblatt, A.D., Chang, J., Himelhoch, S., Welsh, C., 2018. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am. J. Addict. 27, 612-617.